Stock screenerAll disclosures →
EDGAR →
IBRX
Conviction 35HealthcareScan · Mon, Aug 10, 2026IBRX$7.50-1.83%
ResistanceSupportVol 14Insider sellVol MA14 10.06M
May 11May 28Jun 16Jul 6Jul 23Aug 10
WSB mentions · 24h changelatest +200.00%· 3 mentions
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price7.50
Change-1.83%
Gap-1.57%
Rel volume0.98×
Avg volume9.38M
Avg $ vol68.82M
SMA 207.38
SMA 507.62
SMA 2006.06
Price vs 50-1.62%
Price vs 200+23.75%
MA stackmixed
50/200 cross—
Supertrenddown · 8.27
RSI (14)50
MACD hist0.04
MACD crossbull · 1d
Stoch %K / %D59 / 57
ADX (14)11
+DI / −DI20 / 19
RSI divergence—
MACD divergence—
ATR %+6.14%
ADR %5.58%
52w high11.55
52w low1.98
From 52w high-35.06%
Above 52w low+278.79%
New 52w highNo
SqueezeOn · 2d
Bollinger width17.42%
%B0.60
Donchian pos57.05%
Donchian high8.14
Donchian low6.65
AVWAP (52w high)8.10
vs AVWAP high-7.45%
AVWAP (52w low)6.83
vs AVWAP low+9.74%
OBV trendDown
Chaikin MF (20)-0.04
Today vs 20d0.98×
Avg vol (14d)10.06M
Avg vol (20d)9.38M
Avg $ vol (20d)68.82M
Market cap7.95B
RS 3m (vs SPY)-7.24%
RS 6m (vs SPY)+21.35%
RS line new highNo
Trend template5/8
Technical rank58.9
1 week+4.90%
1 month-8.76%
3 months-11.87%
6 months+23.97%
1 year+211.85%
YTD+271.29%
P/E-22.62
P/B-7.59
P/S70.16
P/FCF-25.74
EPS-0.3800
Div yield—
ROE33.57%
ROA-55.91%
Debt/Eq-0.00
Current5.72
EV/EBITDA-32.74
Gross margin—
Net margin-310.18%
Rev growth668.31%
EPS growth15.03%
Price target13.00
Target upside73.33%
Analyst ratingBuy
Institutional21.12%
Ent. value7.87B
Revenue51.24M
Net income-230.38M
Gross profit—
Free cash flow-308.78M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out1.05B
Employees691
ListedWed, Mar 10, 2021
Free float368.17M
Float %35.8%
Short interest134.4M
Days to cover11.9d
Short volume56.8%
Squeeze score76 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.08 vs −$0.09
Last surprise+11.1% beat
Setup gradeD
Conviction35 / 100
Pattern quality—
Tech rank58.9 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance8.87
Support6.68
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in IBRX
No recent disclosed trades by Congress in IBRX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in IBRX · 6 buys · 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Wendel Bruce Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
BLASZYK MICHAEL D Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Cohen Cheryl Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Clark Wesley Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Selecky Christobel Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
MAXWELL LINDA Director · Stock Option (right to buy) · 2026-06-09 | Grant | 65.6K | $0 | 2026-06-09 | 2026-06-10 |
Simon Barry J. Director · Common Stock · 2026-06-04 | Sell | 23.03K | $165K | 2026-06-04 | 2026-06-05 |
SEC filings
EDGAR filings in IBRX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.